CAMBRIDGE, England, November 5, 2026 – 4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced DNA for new genomic medicines, today announced its enzymatic ssDNA Platform is the winner of “Synthetic Biology Innovation of the Year” in the sixth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
4basebio’s ssDNA platform delivers enzymatically produced single-stranded DNA (ssDNA), giving researchers longer, more stable DNA templates to work with as they design increasingly complex gene-editing therapies. 4basebio’s proprietary, cell-free enzymatic process produces high-purity templates up to 10,000 nucleotides long, supporting larger, more complex gene insertions.
Protected ends help shield the DNA from degradation in the cell, while the absence of bacterial sequences avoids the risk of antibiotic-resistance gene insertion. The platform provides biopharma with high-purity, long-form ends protected ssDNA templates designed to address CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics. 4basebio has reported enhanced homology-directed repair (HDR) editing efficiency while maintaining viability in sensitive primary cell types.
“The genomic medicines of tomorrow cannot be developed using the tools and technology of today, starting with the DNA itself. The growth of gene editing and need for complex ‘knock-in’ applications has increased the demand for longer, purer and safer DNA templates. Our platform overcomes the manufacturing and performance bottlenecks associated with traditional chemical synthesis,” said Amy Walker, CEO of 4basebio. “I’m honored to accept this award from BioTech Breakthrough on behalf of our whole team. Our vision is that synthetically enzymatically produced DNA will drive progress across a variety of therapeutic areas, including rare and hard-to-treat diseases. The hope is that better tools for researchers will lead to new treatments for patients who have few or no options today.”
The life sciences and biotechnology sector is rapidly redefining how diseases are discovered, diagnosed and treated, transforming one of the world's most critical industries. From genomics and gene editing to AI-powered drug discovery, cell and gene therapies, and advanced bioprocessing, biotechnology is delivering faster breakthroughs, more personalized care and better outcomes for patients around the world.
The mission of the annual BioTech Breakthrough Awards program is to recognize the innovators transforming the global biotechnology and life sciences landscape with breakthrough technology. The program conducts a comprehensive analysis of the companies redefining how therapies are researched, developed, manufactured and delivered. From AI-driven drug discovery platforms and precision medicine to synthetic biology, bioinformatics, and next-generation diagnostics and biomanufacturing, these innovations are enabling life sciences organizations to accelerate research, reduce development costs, bring life-changing treatments to market faster, and shape the future of human health.
“4basebio’s enzymatically produced ssDNA templates accommodate the complexity of new and emerging therapies. New technology, like synthetic DNA, reminds us of the promise of the field. But reaching that promise requires attention, including the starting materials available to researchers. Double-stranded DNA can be toxic to cells, while chemically synthesized oligonucleotides are restricted in length,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “By enabling researchers to pursue more sophisticated gene therapies, 4basebio’s ssDNA delivers more room to innovate and investigate ideas in the lab that weren’t previously possible due to limitations. We’re awarding 4basebio with ‘Synthetic Biology Innovation of the Year.’”
####
About 4basebio
4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.
For more information, visit 4basebio.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.